News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
721,081 Results
Type
Article (40869)
Company Profile (267)
Press Release (679935)
Multimedia
Podcasts (80)
Webinars (17)
Section
Business (204652)
Career Advice (2022)
Deals (35531)
Drug Delivery (110)
Drug Development (81369)
Employer Resources (173)
FDA (16401)
Job Trends (14941)
News (346345)
Policy (32721)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2565)
Accelerated approval (31)
Adcomms (24)
Allergies (137)
Alliances (49575)
ALS (167)
Alzheimer's disease (1658)
Antibody-drug conjugate (ADC) (305)
Approvals (16666)
Artificial intelligence (500)
Autoimmune disease (143)
Automation (37)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (187)
Biotechnology (174)
Bladder cancer (157)
Brain cancer (55)
Breast cancer (631)
Cancer (4749)
Cardiovascular disease (395)
Career advice (1707)
Career pathing (35)
CAR-T (275)
CDC (44)
Celiac Disease (2)
Cell therapy (728)
Cervical cancer (36)
Clinical research (69485)
Collaboration (1666)
Company closure (4)
Compensation (1138)
Complete response letters (52)
COVID-19 (2707)
CRISPR (87)
C-suite (810)
Cystic fibrosis (143)
Data (6144)
Decentralized trials (2)
Denatured (25)
Depression (130)
Diabetes (495)
Diagnostics (6669)
Digital health (44)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (241)
Drug pricing (184)
Drug shortages (28)
Duchenne muscular dystrophy (225)
Earnings (90034)
Editorial (55)
Employer branding (21)
Employer resources (151)
Events (117170)
Executive appointments (958)
FDA (19474)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (23)
Funding (1444)
Gene editing (191)
Generative AI (42)
Gene therapy (581)
GLP-1 (962)
Government (4651)
Grass and pollen (6)
Guidances (383)
Healthcare (18867)
HIV (55)
Huntington's disease (44)
IgA nephropathy (81)
Immunology and inflammation (244)
Immuno-oncology (53)
Indications (103)
Infectious disease (2965)
Inflammatory bowel disease (186)
Inflation Reduction Act (14)
Influenza (110)
Intellectual property (242)
Interviews (315)
IPO (16638)
IRA (49)
Job creations (3641)
Job search strategy (1427)
JPM (56)
Kidney cancer (15)
Labor market (83)
Layoffs (545)
Leadership (30)
Legal (7948)
Liver cancer (91)
Longevity (14)
Lung cancer (638)
Lymphoma (371)
Machine learning (42)
Management (59)
Manufacturing (776)
MASH (161)
Medical device (13753)
Medtech (13805)
Mergers & acquisitions (19950)
Metabolic disorders (1250)
Multiple sclerosis (155)
NASH (16)
Neurodegenerative disease (307)
Neuropsychiatric disorders (86)
Neuroscience (2864)
Neurotech (1)
NextGen: Class of 2026 (6519)
Non-profit (4508)
Now hiring (65)
Obesity (586)
Opinion (256)
Ovarian cancer (164)
Pain (195)
Pancreatic cancer (222)
Parkinson's disease (279)
Partnered (33)
Patents (486)
Patient recruitment (469)
Peanut (55)
People (58804)
Pharmaceutical (62)
Pharmacy benefit managers (29)
Phase 1 (21664)
Phase 2 (30580)
Phase 3 (22788)
Pipeline (5071)
Policy (278)
Postmarket research (2564)
Preclinical (9190)
Press Release (64)
Prostate cancer (234)
Psychedelics (47)
Radiopharmaceuticals (277)
Rare diseases (813)
Real estate (5953)
Recruiting (69)
Regulatory (24409)
Reports (51)
Research institute (2383)
Resumes & cover letters (351)
Rett syndrome (27)
RNA editing (16)
RSV (76)
Schizophrenia (146)
Series A (237)
Series B (184)
Service/supplier (11)
Sickle cell disease (95)
Special edition (21)
Spinal muscular atrophy (157)
Sponsored (41)
Startups (3612)
State (2)
Stomach cancer (17)
Supply chain (104)
Tariffs (84)
The Weekly (53)
Vaccines (983)
Venture capital (86)
Weight loss (376)
Women's health (87)
Worklife (18)
Date
Last 7 days (591)
Last 30 days (2084)
Last 365 days (29728)
2026 (2811)
2025 (30172)
2024 (35215)
2023 (40075)
2022 (51174)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32108)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (736)
Alabama (83)
Alaska (7)
Arizona (305)
Arkansas (13)
Asia (39184)
Australia (6404)
California (11153)
Canada (3249)
China (1082)
Colorado (471)
Connecticut (469)
Delaware (332)
Europe (84413)
Florida (1660)
Georgia (353)
Hawaii (3)
Idaho (61)
Illinois (850)
India (62)
Indiana (513)
Iowa (22)
Japan (417)
Kansas (125)
Kentucky (38)
Louisiana (26)
Maine (72)
Maryland (1369)
Massachusetts (7985)
Michigan (319)
Minnesota (621)
Mississippi (5)
Missouri (125)
Montana (31)
Nebraska (28)
Nevada (121)
New Hampshire (78)
New Jersey (2965)
New Mexico (28)
New York (2939)
North Carolina (1433)
North Dakota (8)
Northern California (5435)
Ohio (329)
Oklahoma (21)
Oregon (41)
Pennsylvania (2252)
Puerto Rico (22)
Rhode Island (47)
South America (1107)
South Carolina (65)
South Dakota (1)
Southern California (4339)
Tennessee (172)
Texas (1718)
United States (39529)
Utah (333)
Vermont (1)
Virginia (256)
Washington D.C. (81)
Washington State (913)
West Virginia (4)
Wisconsin (106)
Wyoming (2)
721,081 Results for "dermbiont inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
DermBiont Announces 2024 Development Pipeline Update for its First-in-Class Targeted Topical Therapeutics for Seborrheic Keratoses, Basal Cell Carcinomas, and Melasma
DermBiont announced updates on the company’s development pipeline, including the completion of enrollment in a Phase 2b clinical trial of SM-020 gel 1.0% for the treatment of SKs, and anticipated clinical milestones for 2024.
February 22, 2024
·
5 min read
Genetown
DermBiont Announces First Close of $35.2 Million in a Series B Financing to Advance First-in-Class Targeted Topical Dermatological Therapeutics
DermBiont, a clinical-stage biotechnology company that is advancing targeted topical therapeutics for the treatment of dermatological indications, today announced a $35.2 million Series B financing, including a $27.1 million Series B first close and $8.1 million in converting outstanding notes.
October 24, 2023
·
4 min read
Drug Development
DermBiont Announces Positive Data from a Phase 2 Trial Treating Solar Lentigos and Normalizing Pigmentation of the Skin with 0.8% SM-030 Topical Gel
DermBiont, a clinical-stage biotechnology company that is advancing targeted topical therapeutics for the treatment of dermatological indications, today announced positive data from its Phase 2 trial with 0.8% SM-030 gel, a product under development capable of regulating pigmentation by controlling the formation of new melanin.
May 30, 2023
·
6 min read
Drug Development
DermBiont Presents Positive Phase 2 Trial Data Treating Seborrheic Keratosis with SM-020 Topical Gel at American Academy of Dermatology Annual Meeting
DermBiont today announced that its Phase 2 adaptive design trial with of investigational drug SM-020 gel 1.0% met its primary endpoint of a one point improvement in Physician’s lesion assessment (PLA) score at last visit and safety via local tolerability, as well as key multiple secondary endpoints including complete clearance of treated lesions.
March 22, 2023
·
6 min read
Press Releases
Repare Announces Completion of Acquisition by XenoTherapeutics, Inc.
January 29, 2026
·
6 min read
Genetown
DermBiont Raises $28 Million and Acquires Chromaderm to Expand Targeted Topical Therapeutics in Development
DermBiont announced today that it has raised a $28 million Series A2 financing in parallel with the acquisition of clinical-stage biotechnology company Chromaderm.
December 21, 2021
·
4 min read
Press Releases
Encision Inc. Announces Fiscal 2026 Third Quarter Results
February 4, 2026
·
1 min read
Press Releases
Therma Bright Inc. Investee Company, InStatin Expands its Inhaled Statin Programs to include COPD (Chronic Obstructive Pulmonary Disease) as its Lead Indication.
Includes Asthma in its strategic plans and Strengthens its Team in 2024-2025
December 18, 2025
·
5 min read
Press Releases
ABS Bio, Inc. acquires Cureline, Inc. to strengthen support of biopharma drug discovery
January 7, 2026
·
1 min read
Press Releases
DW Healthcare Partners Announces Sale of LKC Technologies to AMETEK, Inc.
February 3, 2026
·
2 min read
1 of 72,109
Next
